Company intelligence / Profile preview

Spindle Acquisition

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Spindle Biotech developed a proprietary RNA polymerase that, when paired with chemically modified IVT DNA templates, significantly reduces dsRNA impurities and enables higher-yield, higher-quality mRNA synthesis for therapeutics and vaccines. The technology is now integrated into the LineaIVT™ platform commercialized by Applied DNA Sciences. No direct clinical results, as Spindle is a platform provider.

Therapeutic areas: OtherInfectious Diseases
Modalities: mRNA-based drugsEnzyme (RNA polymerase)
Industry: Non-Drug Biotech

Partnerships

Applied DNA Sciences (prior to acquisition, collaborative agreement for mRNA platform development)

Beyond the preview

Go deeper on Spindle Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spindle Acquisition.

Explore the full profile